Elevated depressive affect is associated with adverse cardiovascular outcomes among African Americans with chronic kidney disease - PubMed (original) (raw)

Multicenter Study

doi: 10.1038/ki.2011.153. Epub 2011 Jun 1.

Paul L Kimmel, Tom Greene, Jennifer J Gassman, Xuelei Wang, Deborah H Brooks, Jeanne Charleston, Donna Dowie, Denyse Thornley-Brown, Lisa A Cooper, Marino A Bruce, John W Kusek, Keith C Norris, James P Lash; AASK Study Group

Collaborators, Affiliations

Multicenter Study

Elevated depressive affect is associated with adverse cardiovascular outcomes among African Americans with chronic kidney disease

Michael J Fischer et al. Kidney Int. 2011 Sep.

Abstract

This study was designed to examine the impact of elevated depressive affect on health outcomes among participants with hypertensive chronic kidney disease in the African-American Study of Kidney Disease and Hypertension (AASK) Cohort Study. Elevated depressive affect was defined by Beck Depression Inventory II (BDI-II) thresholds of 11 or more, above 14, and by 5-Unit increments in the score. Cox regression analyses were used to relate cardiovascular death/hospitalization, doubling of serum creatinine/end-stage renal disease, overall hospitalization, and all-cause death to depressive affect evaluated at baseline, the most recent annual visit (time-varying), or average from baseline to the most recent visit (cumulative). Among 628 participants at baseline, 42% had BDI-II scores of 11 or more and 26% had a score above 14. During a 5-year follow-up, the cumulative incidence of cardiovascular death/hospitalization was significantly greater for participants with baseline BDI-II scores of 11 or more compared with those with scores <11. The baseline, time-varying, and cumulative elevated depressive affect were each associated with a significant higher risk of cardiovascular death/hospitalization, especially with a time-varying BDI-II score over 14 (adjusted HR 1.63) but not with the other outcomes. Thus, elevated depressive affect is associated with unfavorable cardiovascular outcomes in African Americans with hypertensive chronic kidney disease.

PubMed Disclaimer

Conflict of interest statement

DISCLOSURE

All the authors declared no competing interests.

Figures

Figure 1

Figure 1. Association between baseline elevated depressive affect and adverse clinical outcomes

Cumulative incidence plotted against time from cohort enrollment by the presence of baseline elevated depressive affect for (a) all-cause death, (b) for the kidney disease composite (treating death as a competing risk), and (c) for the CV composite (treating both death and ESRD as competing risks). BDI, Beck Depression Inventory; CV, cardiovascular; ESRD, end-stage renal disease.

Similar articles

Cited by

References

    1. Kimmel PL, Peterson RA, Weihs KL, et al. Multiple measurements of depression predict mortality in a longitudinal study of chronic hemodialysis patients. Kidney Int. 2000;57:2093–2098. - PubMed
    1. Lopes AA, Bragg J, Young E, et al. Depression as a predictor of mortality and hospitalization among hemodialysis patients in the United States and Europe. Kidney Int. 2002;62:199–207. - PubMed
    1. Lopes AA, Albert JM, Young EW, et al. Screening for depression in hemodialysis patients: associations with diagnosis, treatment, and outcomes in DOPPS. Kidney Int. 2004;66:2047–2053. - PubMed
    1. Hedayati SS, Grambow SC, Szczech LA, et al. Physician-diagnosed depression as a correlate of hospitalization in patients receiving long-term hemodialysis. Am J Kidney Dis. 2005;46:642–649. - PubMed
    1. Drayer RA, Piraino B, Reynolds CF, et al. Characteristics of depression in hemodialysis patients: symptoms, quality of life and mortality risk. Gen Hosp Psychiatry. 2006;28:306–312. - PubMed

Publication types

MeSH terms

Grants and funding

LinkOut - more resources